Los Angeles Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.3K | Sell |
279
-4,446
| -94% | -$98.8K | ﹤0.01% | 2066 |
|
|
2025
Q4 | $101K | Buy |
+4,725
| New | +$112K | ﹤0.01% | 1414 |
|
|
2025
Q3 | – | Sell |
-11,475
| Closed | -$274K | – | 1496 |
|
|
2025
Q2 | $274K | Sell |
11,475
-41,645
| -78% | -$1.05M | ﹤0.01% | 1081 |
|
|
2025
Q1 | $1.32M | Sell |
53,120
-22,967
| -30% | -$550K | 0.01% | 491 |
|
|
2024
Q4 | $1.43M | Sell |
76,087
-69,843
| -48% | -$1.23M | 0.01% | 520 |
|
|
2024
Q3 | $2.2M | Buy |
145,930
+131,934
| +943% | +$2.26M | 0.01% | 437 |
|
|
2024
Q2 | $400K | Sell |
13,996
-11,192
| -44% | -$319K | ﹤0.01% | 921 |
|
|
2024
Q1 | $736K | Buy |
+25,188
| New | +$774K | ﹤0.01% | 777 |
|
|
2023
Q4 | – | Sell |
-32,270
| Closed | -$990K | – | 1212 |
|
|
2023
Q3 | $990K | Buy |
32,270
+139
| +0.4% | +$5.01K | ﹤0.01% | 644 |
|
|
2023
Q2 | $1.29M | Buy |
+32,131
| New | +$1.33M | 0.01% | 592 |
|
|
2022
Q4 | – | Sell |
-8,002
| Closed | -$426K | – | 1256 |
|
|
2022
Q3 | $426K | Hold |
8,002
| – | – | ﹤0.01% | 965 |
|
|
2022
Q2 | $467K | Sell |
8,002
-2,279
| -22% | -$149K | ﹤0.01% | 991 |
|
|
2022
Q1 | $785K | Buy |
10,281
+731
| +8% | +$48.7K | ﹤0.01% | 860 |
|
|
2021
Q4 | $575K | Sell |
9,550
-47
| -0.5% | -$2.59K | ﹤0.01% | 941 |
|
|
2021
Q3 | $537K | Sell |
9,597
-425
| -4% | -$24.5K | ﹤0.01% | 1015 |
|
|
2021
Q2 | $608K | Sell |
10,022
-3,255
| -25% | -$206K | ﹤0.01% | 1088 |
|
|
2021
Q1 | $931K | Sell |
13,277
-10,791
| -45% | -$771K | ﹤0.01% | 926 |
|
|
2020
Q4 | $1.44M | Buy |
24,068
+275
| +1% | +$16.1K | 0.01% | 783 |
|
|
2020
Q3 | $1.43M | Sell |
23,793
-21,054
| -47% | -$1.22M | 0.01% | 682 |
|
|
2020
Q2 | $2.35M | Buy |
44,847
+483
| +1% | +$20.2K | 0.01% | 573 |
|
|
2020
Q1 | $1.49M | Buy |
44,364
+39,725
| +856% | +$1.65M | 0.01% | 613 |
|
|
2019
Q4 | $210K | Sell |
4,639
-6,576
| -59% | -$279K | ﹤0.01% | 1192 |
|
|
2019
Q3 | $427K | Sell |
11,215
-9,345
| -45% | -$373K | ﹤0.01% | 1028 |
|
|
2019
Q2 | $894K | Sell |
20,560
-4,060
| -16% | -$172K | ﹤0.01% | 879 |
|
|
2019
Q1 | $937K | Buy |
24,620
+12,060
| +96% | +$471K | 0.01% | 876 |
|
|
2018
Q4 | $540K | Buy |
12,560
+2,545
| +25% | +$119K | ﹤0.01% | 947 |
|
|
2018
Q3 | $492K | Buy |
10,015
+270
| +3% | +$11.7K | ﹤0.01% | 1103 |
|
|
2018
Q2 | $312K | Buy |
+9,745
| New | +$336K | ﹤0.01% | 1275 |
|
|
2015
Q3 | – | Sell |
-3,065
| Closed | -$217K | – | 1209 |
|
|
2015
Q2 | $217K | Buy |
+3,065
| New | +$241K | ﹤0.01% | 1135 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Los Angeles Capital Management's PCRX Position: Q1 2026 in Review
Los Angeles Capital Management reduced its Pacira BioSciences (PCRX) stake by 94% in Q1 2026, selling an estimated $98.8K and leaving 279 shares worth $6.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2066.
Los Angeles Capital Management first reported a position in PCRX in Q2 2015 and has held it in 29 quarters since. The position peaked at $2.35M in Q2 2020. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Los Angeles Capital Management held 279 shares of Pacira BioSciences worth $6.3K as of Q1 2026.
- Los Angeles Capital Management sold 4,446 Pacira BioSciences shares in Q1 2026, an estimated $98.8K.
- Pacira BioSciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2066 holding.
- Los Angeles Capital Management first reported a position in Pacira BioSciences in Q2 2015 and has held it in 29 quarters since.
- Los Angeles Capital Management's Pacira BioSciences position peaked at $2.35M in Q2 2020.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.